Clinical-grade KP-54, MVT-602
Evidence Grade B — Strong clinical evidence. 3212 published studies, 1181 human. 36 registered clinical trials.
This entry covers clinical development programmes for kisspeptin-based treatments — a natural brain hormone that controls the reproductive hormone cascade. The most advanced use is in IVF, where kisspeptin triggers egg maturation without the ovarian hyperstimulation syndrome (OHSS) risk that makes current IVF triggers dangerous for some women. No kisspeptin product is yet approved.
3,212 published studies: 1181 human, 1624 animal, 348 in-vitro, 731 reviews
Clinical kisspeptin programmes represent the most advanced effort to translate kisspeptin biology into a pharmaceutical product. A Phase II IVF trial (60 high-risk patients) achieved 95% oocyte maturation with zero cases of moderate, severe, or critical ovarian hyperstimulation syndrome — the most serious complication of IVF. Live birth rates of 45% per transfer were achieved at the optimal dose.
MVT-602 completed Phase IIa in IVF (60 patients) showing non-inferior oocyte maturation versus the standard GnRH agonist trigger but with a more physiological hormonal profile. The potential to eliminate ovarian hyperstimulation syndrome in high-risk IVF patients represents a significant unmet clinical need. See also kisspeptin-10 (#130) and kisspeptin-54 (#131).
Kisspeptin activates the KISS1R receptor on GnRH neurons, triggering a physiological LH surge for egg maturation in IVF. The resulting hormone response is more natural in amplitude and duration than conventional IVF triggers, which may explain the reduced risk of ovarian hyperstimulation syndrome. MVT-602 achieves a similar physiological response with a longer duration of action.
A Phase II IVF trial at Imperial College London achieved 95% egg maturation with zero cases of moderate, severe, or critical ovarian hyperstimulation syndrome in 60 high-risk patients. Live birth rates of 45% per transfer were achieved at the optimal dose. A longer-acting synthetic version (MVT-602) showed similar results in 60 patients. The potential to eliminate OHSS in high-risk IVF patients addresses a genuine safety gap, but sample sizes remain small and no Phase III trial has been announced. Commercial development timelines are uncertain — the companies involved have other priorities. An intranasal formulation demonstrated in 2025 could improve accessibility if developed further. The kisspeptin pathway also has research interest in conditions like hypothalamic amenorrhoea (loss of periods due to stress or low weight).
Kisspeptin to Quantify GnRH Neuronal Function in Health and Disease
Kisspeptin Administration Subcutaneously to Patients With Hypothalamic Amenorrhea
Functional Proteins in Polycystic Ovary Syndrome
Kissing as a Protective Factor Against Acidic pH in Saliva
A Prospective Cohort Study on the Serum Kisspeptin Levels Throughout Pregnancy in PCOS
The information on this page is provided for educational and research reference purposes only. This is not medical advice. Always consult a qualified healthcare professional before making any health-related decisions.
Histrelin is available as Supprelin LA for central precocious puberty (approved 2007). The Vantas implant for prostate cancer was approved in 2004 but discontinued in 2021. The implant requires a minor surgical procedure for insertion and removal/replacement each year. Supprelin LA's main clinical advantage is its 12-month duration — the longest of any GnRH agonist — which is particularly valuable in paediatric patients where treatment compliance over years is important. Clinical studies demonstrated effective suppression of puberty markers in over 97% of patients. The implant has also seen significant off-label use in gender-affirming care as a puberty blocker, where its annual dosing schedule offers practical benefits for adolescent patients and their families.
Goserelin is marketed as Zoladex by AstraZeneca, available as 3.6 mg monthly and 10.8 mg three-monthly subcutaneous implants. First approved in 1989, it is used in advanced prostate cancer, premenopausal breast cancer, endometriosis, and for thinning the uterine lining before surgical procedures. Goserelin achieves castrate-level testosterone suppression (below 50 ng/dL) within two to four weeks. Its unique implant delivery system means there is no liquid injection, reconstitution, or refrigeration required — a practical advantage in some clinical settings. Like all GnRH agonists, it causes an initial hormone flare before suppression takes effect. Goserelin holds an important niche in breast cancer treatment, where it is used to suppress ovarian function in premenopausal women with hormone-receptor-positive disease, often in combination with aromatase inhibitors.
Nafarelin is marketed as Synarel (approved 1990) for endometriosis and central precocious puberty. It requires administration as one spray in each nostril twice daily — a higher frequency than injectable alternatives but avoids needles entirely, which can be a significant advantage for some patients, particularly children. Clinical trials showed symptom improvement in 75–92% of endometriosis patients. However, absorption can be affected by nasal congestion or concurrent use of nasal decongestants, which can be a practical limitation. As with all GnRH agonists, prolonged use leads to bone density loss, and treatment for endometriosis is typically limited to six months. Nafarelin occupies a niche for patients who prefer non-injectable hormone suppression, though it has become less commonly prescribed as longer-acting depot injections and oral alternatives have become available.
